Carteololum [Inn-Latin]
Brand names,
Carteololum [Inn-Latin]
Analogs
Carteololum [Inn-Latin]
Brand Names Mixture
Carteololum [Inn-Latin]
Chemical_Formula
C16H24N2O3
Carteololum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic2/carteol.htm
Carteololum [Inn-Latin]
fda sheet
Carteololum [Inn-Latin]
msds (material safety sheet)
Carteololum [Inn-Latin]
Synthesis Reference
No information avaliable
Carteololum [Inn-Latin]
Molecular Weight
292.373 g/mol
Carteololum [Inn-Latin]
Melting Point
No information avaliable
Carteololum [Inn-Latin]
H2O Solubility
No information avaliable
Carteololum [Inn-Latin]
State
Solid
Carteololum [Inn-Latin]
LogP
2.037
Carteololum [Inn-Latin]
Dosage Forms
Ophthalmic Solution (1%)
Carteololum [Inn-Latin]
Indication
For the treatment of intraocular hypertension and chronic open-angle glaucoma
Carteololum [Inn-Latin]
Pharmacology
Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Carteololum [Inn-Latin]
Absorption
No information avaliable
Carteololum [Inn-Latin]
side effects and Toxicity
The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.
Carteololum [Inn-Latin]
Patient Information
No information avaliable
Carteololum [Inn-Latin]
Organisms Affected
Humans and other mammals